The annual incidence of Langerhans cell histiocytosis among adults living in Greece.

Makras P, Stathi D, Yavropoulou M, Tsoli M, Kaltsas G.Pediatr Blood Cancer. 2020 Jul 2:e28422. doi: 10.1002/pbc.28422


Bone metabolism in Langerhans cell histiocytosis.

Anastasilakis AD, Tsoli M, Kaltsas G, Makras P.Endocr Connect. 2018 Jul;7(7):R246-R253. doi: 10.1530/EC-18-0186. Epub 2018 Jul 2


Low periostin levels in adult patients with Langerhans cell histiocytosis are independently associated with the disease activity.

Anastasilakis AD, Polyzos SA, Tsoli M, Papatheodorou A, Kokkoris P, Kaltsas G, Terpos E, Makras P.Metabolism. 2017 Jun;71:198-201. doi: 10.1016/j.metabol.2017.03.017. Epub 2017 Apr 4.


Denosumab for the treatment of adult multisystem Langerhans cell histiocytosis.

Makras P, Tsoli M, Anastasilakis AD, Thanou M, Kaltsas G.Metabolism. 2017 Apr;69:107-111. doi: 10.1016/j.metabol.2017.01.004. Epub 2017 Jan 12.


Bisphosphonates in Langerhans Cell Histiocytosis: An International Retrospective Case Series.

Chellapandian D, Makras P, Kaltsas G, van den Bos C, Naccache L, Rampal R, Carret AS, Weitzman S, Egeler RM, Abla O.Mediterr J Hematol Infect Dis. 2016 Jul 1;8(1):e2016033. doi: 10.4084/MJHID.2016.033. eCollection 2016


Langerhans cell histiocytosis and pituitary function.

Makras P, Kaltsas G.Endocrine. 2015 Apr;48(3):728-9. doi: 10.1007/s12020-014-0497-2. Epub 2015 Jan 1.


Rationale for the application of RANKL inhibition in the treatment of Langerhans cell histiocytosis.

Makras P, Salagianni M, Revelos K, Anastasilakis AD, Schini M, Tsoli M, Kaltsas G, Andreakos E.J Clin Endocrinol Metab. 2015 Feb;100(2):E282-6. doi: 10.1210/jc.2014-2654. Epub 2014 Nov 6.


Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net.

Girschikofsky M, Arico M, Castillo D, Chu A, Doberauer C, Fichter J, Haroche J, Kaltsas GA, Makras P, Marzano AV, de Menthon M, Micke O, Passoni E, Seegenschmiedt HM, Tazi A, McClain KL.Orphanet J Rare Dis. 2013 May 14;8:72. doi: 10.1186/1750-1172-8-72


Cladribine therapy in adults with advanced Langerhans cell histiocytosis.

Schini M, Makras P, Kanakis G, Voulgarelis M, Kaltsas G.Leuk Lymphoma. 2013 Jul;54(7):1541-3. doi: 10.3109/10428194.2012.744454. Epub 2012 Nov 26.


Serum osteoprotegerin, RANKL, and Dkk-1 levels in adults with Langerhans cell histiocytosis.

Makras P, Polyzos SA, Anastasilakis AD, Terpos E, Kanakis G, Schini M, Papatheodorou A, Kaltsas GA.J Clin Endocrinol Metab. 2012 Apr;97(4):E618-21. doi: 10.1210/jc.2011-2962. Epub 2012 Jan 25.


Is serum IL-17A a useful systemic biomarker in patients with Langerhans cell histiocytosis?

Makras P, Polyzos SA, Anastasilakis AD, Terpos E, Papatheodorou A, Kaltsas GA.Mol Ther. 2012 Jan;20(1):6-7. doi: 10.1038/mt.2011.239.


Adult case of Langerhans cell histiocytosis with single site vertebral involvement.

Paxinos O, Delimpasis G, Makras P.J Musculoskelet Neuronal Interact. 2011 Jun;11(2):212-4; quiz 214.


Reduced bone mineral density in adult patients with Langerhans cell histiocytosis.

Makras P, Terpos E, Kanakis G, Papatheodorou A, Anastasilakis AD, Kokkoris P, Kaltsas GA.Pediatr Blood Cancer. 2012 May;58(5):819-22. doi: 10.1002/pbc.23166. Epub 2011 May 5.


Distinctive growth pattern in a patient with a delayed diagnosis of Langerhans‘ cell histiocytosis.

Anastasilakis AD, Kaltsas GA, Delimpasis G, Wilkens L, Kanakis G, Makras P.Pituitary. 2012 Dec;15 Suppl 1:S28-32. doi: 10.1007/s11102-011-0291-6.


Cardiovascular risk factors in adult patients with multisystem Langerhans-cell histiocytosis: evidence of glucose metabolism abnormalities.

Alexandraki KI, Makras P, Protogerou AD, Dimitriou K, Stathopoulou A, Papadogias DS, Voidonikola P, Piaditis G, Pittas A, Papamichael CM, Grossman AB, Kaltsas G.QJM. 2008 Jan;101(1):31-40. doi: 10.1093/qjmed/hcm118. Epub 2007 Dec 26.


Systemic and endocrine manifestations of Langerhans‘ cell histiocytosis: current concepts in diagnosis and management.

Makras P, Piaditis G, Kaltsas GA.Expert Rev Endocrinol Metab. 2007 Nov;2(6):773-783. doi: 10.1586/17446651.2.6.773.


Endocrine manifestations in Langerhans cell histiocytosis.

Makras P, Alexandraki KI, Chrousos GP, Grossman AB, Kaltsas GA.Trends Endocrinol Metab. 2007 Aug;18(6):252-7. doi: 10.1016/j.tem.2007.06.003. Epub 2007 Jun 27.


Langerhans’ cell histiocytosis in an adult patient manifested as recurrent skull lesions and Diabetes Insipidus.

Makras P, Papadogias D, Samara C, Zetos A, Kaltsas G, Piaditis G, Chu AC.Hormones (Athens). 2004 Jan-Mar;3(1):59-64. doi: 10.14310/horm.2002.11113.


Spontaneous gonadotrophin deficiency recovery in an adult patient with Langerhans cell histiocytosis (LCH).

Makras P, Papadogias D, Kontogeorgos G, Piaditis G, Kaltsas GA.Pituitary. 2005;8(2):169-74. doi: 10.1007/s11102-005-4537-z.


Evolving radiological features of hypothalamo-pituitary lesions in adult patients with Langerhans cell histiocytosis (LCH).

Makras P, Samara C, Antoniou M, Zetos A, Papadogias D, Nikolakopoulou Z, Andreakos E, Toloumis G, Kontogeorgos G, Piaditis G, Kaltsas GA.Neuroradiology. 2006 Jan;48(1):37-44. doi: 10.1007/s00234-005-0011-x. Epub 2005 Nov 15.